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The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside
(monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with
metastatic cancer were treated with DOX preceded by a 10min i.v. infusion of 1500mgm
 2 monoHER. Five patients were
examined by endomyocardial biopsy after reaching a cumulative dose of 300mgm
 2. Histopathological changes in the
cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean
biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative
doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced
DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients
with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose
of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma
possibly by depleting the glutathione defense system in both heart and tumour.
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The anthracycline doxorubicin (DOX) is widely used in the
treatment of several malignancies in adult and paediatric patients.
Treatment with DOX is limited by a dose-dependent cardio-
toxicity, which may lead to late side effects resulting in severe
morbidity and mortality (Steinherz et al, 2001; Lipshultz et al,
2005). Although the 5-year survival of childhood cancer has
improved from 30 to 70% in the last 40 years, the risk of death
from cardiac events in these survivors is eight times higher than
that in the normal population (Wouters et al, 2005). Besides this,
combining DOX with other anticancer drugs, for example, taxanes
and trastuzumab, increases efficacy, but unfortunately also
augments cardiotoxicity (Seidman et al, 2002; Minotti et al, 2004).
Although the mechanism of DOX-induced cardiotoxicity is still
not fully understood, a major role has been ascribed to the
induction of free radicals (Horenstein et al, 2000; Hrdina et al,
2000; Xu et al, 2001). The cardiomyocyte is particularly vulnerable
to free radical injury because of properties such as a low
antioxidant status (Doroshow et al, 1980; Iarussi et al, 2000).
Presently, the cardioprotectant dexrazoxane is the only drug with
proven efficacy (Cvetkovic and Scott, 2005). A recent review
recommended the use of dexrazoxane if the risk of cardiotoxicity is
high. However, clinicians should weigh its cardioprotective effect
against the risk of a possible decrease of antitumour activity (Van
Dalen et al, 2005). Preclinical experiments showed that the
flavonoid 7-monohydroxyethylrutoside (monoHER) is a potential
protective agent against DOX-induced cardiotoxicity without
interfering with its antitumour activity (Van Acker et al, 1997,
2000). Radical scavenging and iron chelating properties are the
supposed mechanisms of action of monoHER (Haenen et al, 1993;
Van Acker et al, 1993). No serious side effects were observed in a
clinical phase I study up to a dose of 1500mgm
 2. At this dose, the
pharmacokinetic end points were reached, that is, Cmax and AUC
N
were comparable to those obtained in mice under protecting
conditions. Therefore, this dose was evaluated in a phase II study
(Willems et al, 2006).
In the present study, we evaluated the cardioprotective proper-
ties of 1500mgm
 2 monoHER given as a 10min i.v. infusion
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sbefore DOX in patients with metastatic cancer. For the early
sensitive and specific detection of DOX-induced cardiotoxicity,
endomyocardial biopsies were taken (Meinardi et al, 1999).
MATERIALS AND METHODS
Patient selection
Patients with metastatic solid tumours were entered when they
received a DOX-based chemotherapy regimen with a dosage of
DOXX50mgm
 2 per cycle and an infusion duration p1h.
Patients had a WHO performance status of p2 and a life
expectancy of X3 months. They also had adequate organ
functions. Their left ventricular ejection fraction (LVEF), measured
by multigated radionuclide angiography, was 450%. Patients were
excluded if they had received prior anthracyclines, had prior or
actual cardiovascular disease or had prior radiotherapy to the
mediastinum.
All patients gave written informed consent and the protocol was
approved by the Medical Ethical Review Committee of the VU
University Medical Center (VUMC). Patients were enrolled
between September 2003 and March 2006.
Treatment
7-Monohydroxyethylrutoside was provided by Novartis Consumer
Health (Nyon, Switzerland). The drug was formulated by the
Department of Pharmacy, VUMC, Amsterdam as described before
(Willems et al, 2006). Formulated DOX (doxorubicin hydrochloride,
2mgml
 1) was obtained from Pharmachemie B.V. (Haarlem,
the Netherlands).
7-Monohydroxyethylrutoside was administered i.v. in 10min at
a dose of 1500mgm
 2 60min before every DOX administration. If
cardiotoxicity would be observed in the first three evaluable
patients, administration according to this dosing scheme would be
changed and a following patient would receive DOX infusion either
immediately after monoHER (because in plasma and heart, Cmax of
monoHER is obtained immediately after the end of infusion; Abou
El Hassan et al, 2003; Willems et al, 2006) or with an interval of 2h
(to give monoHER the opportunity to convert into an active
metabolite, if any). If cardiotoxicity was maintained in both
patients, then the study would be finished. If one of the two
patients shows cardioprotection, then 10 additional patients will be
treated with the protecting scheme.
Patient evaluation
Before starting, patients were evaluated by a full blood count,
serum biochemistry including liver function tests, lactate dehy-
drogenase, and cholesterol. Risk factors for cardiovascular disease
were also evaluated. An LVEF and an ECG were performed before
entry into the study.
Every subsequent administration of monoHER and DOX was
preceded by a full blood count, liver enzymes, serum creatinine
and a routine 12-lead ECG. A complete blood count was also done
10 days after chemotherapy.
After a cumulative dose of 300mgm
 2 DOX, an endomyocardial
biopsy was performed and the LVEF was measured. The latter was
repeated at least 3 weeks after the last dose of DOX with a biopsy if
possible. For logistic reasons, the biopsy of patient no. 8 was done
after a cumulative dose of 375mgm
 2 DOX.
Endomyocardial biopsy
During a left heart catheterisation, a 104cm, seven french biopsy
forceps was used to obtain tissue from the left ventricle. Three to
four specimens 0.5–1mm in diameter were obtained. The speci-
mens were fixed in 4% buffered formaldehyde and prepared for
electron microscopy.
Histological analysis and biopsy scores
After fixation in 4% buffered formaldehyde, the heart tissue was
post fixed in 1% osmium tetroxide. The tissue was then dehydrated
through a graded series of ethanol solutions of 70–95% and
embedded in JB-4 Plus resin. Thereafter, 0.5–3.0mm thick sections
were cut with a glass knife. These semithin sections were processed
for electron microscopy. Cardiomyocytes with 42 microvacuoles,
macrovacuoles and/or loss of myofibrils were counted as deviant.
The morphological grade determined from the specimens exam-
ined by electron microscopy was scored on a six-point scale
previously described by Billingham et al (1978) (Bristow et al,
1982): in grade 0, cells are normal; in grade 1, 1.5, 2 and 2.5 deviant
cells are o5, 5–15, 16–25 and 26–35%, respectively; in grade 3,
cell damage is 435%.
Off-study criteria
Patients went off study in case of progressive disease, a serious
cardiac event or other events that precluded further treatment.
Criteria described by Shapiro et al (1999) were used for diagnosis
of cardiac events. Episodes of cardiac dysfunction were char-
acterised according to the NYHA functional classification
(Seidman et al, 2002).
Assessment of tumour response
Assessment of tumour response was carried out every 2–3 cycles
by CT scan, using standard ECOG criteria (Oken et al, 1982).
Statistical analysis
This trial was an open-labelled, controlled study. We compared the
data of our patients with those of 14 patients from the study of
Torti et al (1986) treated with a cumulative dose of DOX between
200 and 300mgm
 2 alone using the w
2 test. Our hypothesis was
that adding monoHER to DOX would eliminate its cardiotoxicity
up to a cumulative dose of at least 300mgm
 2, which was the
upper limit of the dose interval of DOX from Torti’s patients. To
achieve a power of 80%, 11 patients would be required. This
sample size was obtained when applying the w
2 test with
significance level 0.05 and assuming a response rate (i.e. no
cardiac damage) in the experimental arm of 80%. If at least five
patients show DOX-induced damage, statistical significance cannot
be achieved anymore and the study should be stopped.
RESULTS
Eight patients meeting the inclusion criteria were enrolled
(Table 1).
Analysis of risk factors indicated that patient no. 6 was treated
for hyperhomocysteinaemia. Two other patients had an elevated
body mass index of 29.1 (no. 1) and 30.1 (no. 7), indicating
overweight and obesity, respectively. Patient no. 2 had hyperlipi-
daemia (LDL of 6.3mmoll
 1; normal values p5.0). None of the
other patients had risk factors for cardiovascular disease. All
patients were classified as NYHA class
2 and had a performance
status (WHO) p2.
Five patients received a cumulative dose of X300mgm
 2 DOX
and underwent a biopsy. In the other three patients, DOX was
discontinued before this dose, due to progressive disease.
Patient no. 3 received irradiation after he was operated for a
parapharyngeal tumour with a modified radical neck dissection at
his right site because of a malignant peripheral nerve sheet
tumour. Both patient nos. 7 and 8 received postoperative
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their right upper leg.
Treatment with DOX preceded by monoHER
During monoHER infusion, two patients reported adverse events.
One patient described a sensation of fullness in his stomach, which
developed during infusion of monoHER and disappeared soon
after the end of the infusion. The other patient experienced itching
in the skin of the neck during monoHER infusion and disappear-
ing rapidly after the infusion. Both patients experienced the events
during each cycle. A causal relationship cannot be excluded. The
other six patients did not experience adverse events.
None of the patients had a delay in receiving subsequent cycles
of chemotherapy. As expected, all patients developed chemother-
apy-related leukopaenia, which recovered before the start of the
next cycle. No disturbances of liver enzymes and serum creatinine
were noted.
Biopsy scores
The endomyocardial biopsy scores are shown in Table 2. After
300mgm
 2, the first three evaluable patients showed abnormal-
ities consistent with DOX-induced cardiotoxicity, that is the
presence of microvacuoles dominated (Figure 1). In patient nos. 3
and 4, microvacuoles were present in 52 and 20% of the
cardiomyocytes, respectively. In patient no. 6, 33% of the
cardiomyocytes had 42 small vacuoles per cardiomyocyte.
Because each of the first three evaluable patients showed
cardiotoxicity, it was decided to stop this dosing scheme. The
time interval between monoHER and DOX administration was
changed and patient no. 7 received DOX immediately after
monoHER. In the biopsy of this patient, microvacuolisation was
observed in 60% of the cardiomyocytes. After this result, the
interval was changed again and patient no. 8 received DOX 2h
after monoHER administration. In this patient, microvacuolisation
was detected in 49% of the cardiomyocytes. After these results, the
study had to be considered negative, because no cardioprotective
effect of monoHER was observed in the five patients.
Second biopsies were also taken after 450–480mgm
 2 of DOX
in two patients (Table 3). The score of patient no. 4 had increased
from 2.0 to 2.5, whereas the score of patient no. 3 remained 3.
Striking was the increase in loss of myofibrils in addition to the
microvacuoles observed in the cardiomyocytes after 300mgm
 2
(Figure 2).
Ten months after his last cycle of DOX, patient no. 4 underwent
a third biopsy. This time, the cardiomyocytes showed recuperation
of myofibrils, whereas the number of abnormal cardiac cells
(microvacuolisation) was less than that in the first two biopsies
(score 2).
No complications occurred during the seven biopsy procedures
in the first four patients. However, the last patient (no. 8)
developed a small pericardial effusion after the biopsy. This was
preceded by chest pain and transient supraventricular rhythm
disturbances. These sequelae disappeared within a few days and
after a week she recovered and received the sixth cycle of DOX.
Monitoring and evaluation of cardiac function
In all patients, the ECG remained unchanged during therapy and
no cardiac dysfunction occurred.
Table 1 Patient characteristics
Patient no. Age/sex Diagnosis Total dose of DOX (mgm
 2) Response on DOX Biopsy
01 62/F Breast cancer 100 PD N
02 54/F Adrenal cortical cancer 150 PD N
03 25/M Malignant peripheral nerve sheet tumour 480 PR Y
04 64/M Malignant fibrous histiocytoma 450 PR Y
05 55/F Breast cancer 100 PD N
06 48/F Breast cancer 300 SD Y
07 45/F Malignant fibrous histiocytoma 300 PR Y
08 56/F Malignant fibrous histiocytoma 375 SD Y
Age in years; sex F female, M male; assessment of tumour response was done by using standard ECOG criteria (PD¼progressive disease; PR¼partial remission; SD¼stable
disease); Y¼yes; N¼no.
Table 2 Patients who received at least a cumulative dose (cum. dose) of
300mgm
2 DOX and underwent an endomyocardial biopsy
Patient
no.
Biopsy score cum. dose (no. of
cycles dose per cycle, time of bolus
infusion/Dt/grade
LVEF
before
dox
LVEF after
X300mgm
 2
03 300 (4 75, 150)/60/grade 3 71% 67%
04 300 (4 75, 150)/60/grade 2 72% 60%
06 300 (6 50, 150)/60/grade 2.5 52% ND
07 300 (4 75, 150)/10/grade 3 75% 63%
08 375 (5 75, 150)/120/grade 3 65% 63%
Dt¼time between end of monoHER infusion and start of DOX infusion in minutes.
The morphological grade was scored on a six-point scale previously described by
Billingham and Bristow; LVEF¼left ventricular ejection fraction.
Figure 1 Heart tissue from patient no. 3 after 300mgm
 2 DOX.
Evaluation by electron microscopy demonstrated an abundant presence of
microvacuoles in the cardiomyocytes.
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 2 DOX started
with an LVEF 450% (Table 2). After 300–375mgm
 2 DOX, the
LVEF decreased in 4 out of 5 patients. This decrease was not
related with the biopsy score or the time interval between
monoHER and DOX infusions. Unfortunately, no information on
the LVEF was available for patient no. 6.
After 480mgm
 2 DOX, the LVEF in patient no. 3 decreased to
53%, which is a decline of 25% compared to the LVEF before
starting the study (71%). The patient had no symptoms of cardiac
failure. Ten months after his last cycle of chemotherapy, the LVEF
remained stable and he remained without cardiac symptoms.
The LVEF of patient no. 4 showed an initial drop from 72%
before starting chemotherapy to 60% after 300mgm
 2 DOX
(decline of 415%). This value remained stable up to 450mgm
 2
of DOX, and at 10-month follow-up the patient still had an
excellent physical condition.
Evaluation of tumour response
Response to the chemotherapy was remarkable in the four patients
with metastatic soft-tissue sarcoma (STS). Three of them devel-
oped a partial remission (PR), as observed on the CT scan
(Table 1). In two of these patients (nos. 4 and 7), PR was
maintained up to the present, that is, 30 and 16 months after the
start of chemotherapy, respectively. The other patient (no. 3) had
progressive disease after a PR of 9 months duration. The fourth
patient (no. 8) achieved stable disease for at least 7 months, while
continuing therapy with DOX up to a cumulative dose of
495mgm
 2.
DISCUSSION
On the basis of the promising results with monoHER observed in
preclinical experiments, we performed the present phase II study
in patients with metastatic cancer. The cardioprotective effect of
monoHER on DOX-induced cardiotoxicity was evaluated by
endomyocardial biopsy. However, the results indicated that the
preclinical observations were not translated into protection against
DOX-induced heart damage in humans.
The golden standard for early detection of DOX-induced
cardiotoxicity is the endomyocardial biopsy, because of its
high sensitivity and high specificity (Torti et al, 1986).
Currently, the most common method used to detect DOX-induced
cardiac damage is the evaluation of the LVEF, but usually
at later stages (Kilickap et al, 2005; Villani et al, 2006). For
detection of cardiotoxicity at an earlier stage, the use of
biochemical markers such as atrial and brain natriuretic peptides,
endothelin-1 and also cardiac troponin-T and -I have been
investigated (Yamashita et al, 1995; Suzuki et al, 1998; Kilickap
et al, 2005). However, large-scale studies addressing whether these
biomarkers following DOX treatment will be predictive for the
development of late-onset heart failure are lacking. Therefore,
despite its invasiveness, we chose the endomyocardial biopsy for
this evaluation.
Data of Billingham et al (1978) showed that anthracycline-
induced myocardial damage occurred in nearly all patients treated
with cumulative DOX doses of 240mgm
 2. Therefore, we could
expect detectable heart damage after a cumulative dose of
300mgm
 2, which would allow the registration of protection by
monoHER. However, all five patients undergoing the biopsy
procedure after a median cumulative dose of 300mgm
 2 showed
DOX-induced cardiotoxicity with a mean biopsy score of 2.7
according to Billingham et al (1978). This score was independent
of the time interval between monoHER and DOX infusion and
much higher than the biopsy score of 1.4, which is expected after a
cumulative dose of 300mgm
 2 DOX according to the linear
regression analysis of Torti et al (1986). In our patients, mainly
one of the three morphological changes, that is, small vacuoles of
varying size, was observed after 300mgm
 2 DOX, whereas in Torti
et al’s study also partial or total myofibrillar loss was observed.
However, in Torti’s study, it is not clear after which dose this
occurred. In addition to microvacuolisation, loss of myofibrils was
demonstrated in two patients after higher cumulative doses of
DOX. This suggests that the occurrence of microvacuoles as such is
a marker of cytotoxicity of DOX treatment. Billingham et al (1977)
described that these microvacuoles appear early as a swelling of the
sarcoplasmic reticulum, which eventually coalesce to form large
spaces in the cytoplasm (macrovacuoles). The possible change
from microvacuoles into macrovacuoles in time is not clear from
literature.
Thus, instead of protection, our patients had higher biopsy
scores than the historical controls. However, it should be noted
that the data of Torti et al (1986) were obtained after a cumulative
dose of 200–300mgm
 2 with biopsies from the right ventricle,
whereas biopsies from our patients were obtained after a
cumulative dose of 300mgm
 2 from the left ventricle. Previously,
it was shown that ultrastructural abnormalities of cardiomyocytes
were more pronounced in biopsy specimens from the left ventricle
than those from the right ventricle (Mortensen et al, 1986). In
addition to this, there is a considerable variability in patient
sensitivity to the cardiotoxic effects of DOX (Ferrans 1978; Mason
et al, 1978). These data may explain a possible overestimation of
the toxic effect of DOX on the heart tissue in our patients.
Although heart failure is directly related to the degree of myocyte
damage (Bristow et al, 1978), none of our patients developed heart
failure, although the LVEF dropped by 16% in two patients,
whereas it decreased in two other patients by only 4–6% (in
comparison to the initial LVEF).
Figure 2 Heart tissue from patient no. 3 after 480mgm
 2 DOX. In
addition to the vacuolisation, a loss of myofibrils is observed with electron
microscopy.
Table 3 Two patients who underwent an extra endomyocardial biopsy
at 4300mgm
 2 of DOX
Patient
no.
Cum.dose/biopsy
score/LVEF
Biopsy score/LVEF 10 months after
the last cycle
03 480/grade 3/53% ND/51%
04 450/grade 2.5/66% Grade 2/62%
The morphological grade was scored on a six-point scale previously described by
Billingham and Bristow; LVEF¼left ventricular ejection fraction; ND¼not done.
MonoHER and DOX-induced cardiotoxicity in patients
AME Bruynzeel et al
1087
British Journal of Cancer (2007) 97(8), 1084–1089 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sIn the third biopsy procedure of patient no. 4, the score of the
cardiac tissue had improved. A recuperation of myofibrils in the
cardiomyocytes was observed and the microvacuolisation was less.
These findings are in agreement with a previous study reporting
that some improvement of the histological damage may occur
(Mackay et al, 1994). This is in contrast with other results, which
indicated that DOX-induced cardiotoxicity is an ongoing progres-
sive process (Billingham et al, 1978).
The contrasting effects of monoHER found in animal and
human studies may be attributed to differences in metabolism
between the species. Therefore, patient no. 8 was treated with a 2h
interval. However, this interval change did not reduce DOX-
induced cardiotoxicity. In addition, no metabolites of monoHER
have been detected until now. On the other hand, it cannot be
excluded that during scavenging of the reactive oxygen species, the
antioxidant monoHER is converted into a reactive oxidation
product, which, like the oxidation product of quercetin, may be
prone to form adducts with thiol groups from glutathione and
proteins (Boots et al, 2005a). Depletion of glutathione may in
addition to the low antioxidant status of the cardiomyocyte
(Nowak and Drzwoski, 1996) reduce cardioprotection, while
monoHER-protein adducts may cause additional toxicity (Boots
et al, 2005b).
Another unexpected observation in our study was that three of
the four patients with STS had objective remissions, while the
fourth patient had stable disease. Normally, objective responses on
DOX in STS patients without prior chemotherapy are approxi-
mately 25% (Santoro et al, 1995). Although our observation was
done in a very limited number of patients, our result is much
better than expected, because the chance of observing an objective
response in four consecutive STS patients treated with DOX is
0.4%. Thus, it is suggestive that monoHER enhances the
antitumour activity of DOX in STS.
This observation is in agreement with potentiating antitumour
effects of a few flavonoids observed in vitro (Elangovan et al, 1994;
Sliutz et al, 1996; Debes et al, 2003). The background for this effect
may be that the concentration of GSH may play a role in STS
chemoresistance (Hochwald et al, 1997) and that GSH depletion
may increase the antitumour efficacy (Siemann and Beyers, 1997).
Thus, the same mechanism may play a role as hypothesised for the
cardiomyocytes.
As a consequence of the above-mentioned aspects, there may be
a dose-depending transition in the effect of monoHER, that is a
high dose (X1500mgm
 2) for obtaining a potentiating effect of
the antitumour effect for at least STS and a low dose (somewhere
below 1500mgm
 2) for obtaining cardioprotection. These aspects
have to be elucidated further in the near future. It may be
concluded that monoHER at a dose of 1500mgm
 2 did not protect
against DOX-induced cardiotoxicity in patients with metastatic
disease, but may have an enhancing effect on the antitumour
activity of DOX in patients with metastatic STS. Further preclinical
and clinical investigations seem to be warranted to investigate the
postulated dose-depending transitional effect of monoHER.
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